WallStreetZenWallStreetZen

NASDAQ: DNTH
Dianthus Therapeutics Inc Stock Ownership - Who owns Dianthus Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Dianthus Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Adam M. VenessSVP General Counsel and Sec.2026-06-1730,000$17.88
$536.40kBuy
Adam M. VenessSVP General Counsel and Sec.2026-06-1716,771$80.34
$1.35MSell
Adam M. VenessSVP General Counsel and Sec.2026-06-1713,229$81.38
$1.08MSell
Simrat RandhawaEVP Head of RD2026-06-019,375$22.07
$206.91kBuy
Simrat RandhawaEVP Head of RD2026-06-015,428$89.72
$487.00kSell
Simrat RandhawaEVP Head of RD2026-06-0116,943$90.72
$1.54MSell
Simrat RandhawaEVP Head of RD2026-06-014,159$91.37
$380.01kSell
Simrat RandhawaEVP Head of RD2026-06-013,998$8.44
$33.74kBuy
Simrat RandhawaEVP Head of RD2026-06-016,908$17.88
$123.52kBuy
Simrat RandhawaEVP Head of RD2026-06-016,249$21.77
$136.04kBuy

1 of 7

DNTH insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when DNTH insiders and whales buy or sell their stock.

DNTH Shareholders

What type of owners hold Dianthus Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fairmount Funds Management LLC14.93%8,164,219$778.46MInsider
Fmr LLC14.21%7,767,686$740.65MInstitution
Avidity Partners Management LP7.70%4,208,368$401.27MInstitution
Bruce Booth7.53%4,117,125$392.57MInsider
Gv 2016 GP LLC6.11%3,339,137$318.39MInsider
Blake Byers6.11%3,339,137$318.39MInsider
Blackrock Inc5.81%3,175,703$302.80MInstitution
Atlas Venture Fund X LP5.76%3,148,399$300.20MInsider
Third Rock Ventures IV LP5.59%3,058,204$291.60MInsider
Lei Meng4.97%2,717,554$259.12MInsider

1 of 3

DNTH vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
DNTH65.57%34.43%Net BuyingNet Buying
CAI41.85%58.15%Net SellingNet Selling
MANE62.15%15.06%Net Buying
DFTX63.13%36.87%Net SellingNet Selling
TVTX63.57%36.43%Net SellingNet Selling
View Top Biotech Stocks

Dianthus Therapeutics Stock Ownership FAQ

Who owns Dianthus Therapeutics?

Dianthus Therapeutics (NASDAQ: DNTH) is owned by 117.50% institutional shareholders, 61.71% Dianthus Therapeutics insiders, and 0.00% retail investors. Fairmount Funds Management LLC is the largest individual Dianthus Therapeutics shareholder, owning 8.16M shares representing 14.93% of the company. Fairmount Funds Management LLC's Dianthus Therapeutics shares are currently valued at $781.15M.

If you're new to stock investing, here's how to buy Dianthus Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.